Personalized cancer immunotherapy for aggressive hypoxic tumors with blockbuster potential. Our Target Mechanism For Treating Hypoxic Tumors: Carbonic Anhydrase IX (CA IX). Our Mission: - to fill the gap in treatment of oncology diseases with poor prognosis, - to increase survival rate and bring hope to patients who have undergone different types of therapies without success, - to deliver novel therapeutics that match the principle of personalized medicine which will help patients to improve the quality of their lives. Crunchbase https://www.crunchbase.com/organization/mabpro-therapeutics
| Website | http://www.mabpro.sk |
| Revenue | $2 million |
| Employees | 10 (6 on RocketReach) |
| Founded | 2016 |
| Industry | Biotechnology Research, Business Services General, Business Services |
| Keywords | Cancer Immunotherapy, Oncology, Oncology Therapeutics, Personalized Medicine, Immunotherapy, Targeted Therapy, Cancer Treatment, Novel Therapeutics, Cancer Drugs, Cancer Research, Drug Development, Biotechnology, Pharmaceutical, Clinical Trials |
| Competitors | Regeneron, Amgen, Roche, Genmab, Merck & Co., Inc., Bristol Myers Squibb, Novartis, AbbVie, Pfizer, Lilly India +43 more (view full list) |
| SIC | SIC Code 87 Companies, SIC Code 873 Companies |
| NAICS | NAICS Code 541 Companies, NAICS Code 54 Companies |
Looking for a particular Mabpro Therapeutics employee's phone or email?
Mabpro Therapeutics Questions
The Mabpro Therapeutics annual revenue was $2 million in 2026.
Jaromír Pastorek is the Chairman of the Board of Mabpro Therapeutics.
6 people are employed at Mabpro Therapeutics.
The NAICS codes for Mabpro Therapeutics are [541, 54].
The SIC codes for Mabpro Therapeutics are [87, 873].
Top Mabpro Therapeutics Employees
-
1
-
Richard Imrich
Chief Medical Officer at Mabpro Therapeutics
Trentino-Alto Adige/South Tyrol, Italy1 -
Radoslav Bielka
Shareholder at Mabpro Therapeutics
Bratislava, SK23 -
Viliam Janac
Head Of Legal at Mabpro Therapeutics
Bratislava, SK1
Related Companies
